Render Target: STATIC
Render Timestamp: 2024-11-04T09:50:04.645Z
Commit: 23cb9f61fe67e1e9093fd644a533c4ff516a6463
XML generation date: 2024-09-20 06:23:27.778
Product last modified at: 2024-05-30T07:11:47.386Z
1% for the planet logo
PDP - Template Name: Cellular Dyes
PDP - Template ID: *******0000253

Chromomycin A3 #79929

    Product Information

    Product Usage Information

    Chromomycin A3 is supplied as a lyophilized powder. For a 1 mM stock, reconstitute 5 mg of powder in 0.84 mL of DMSO. Working concentrations and length of treatment can vary depending on the desired effect.

    Storage

    Store lyophilized at -20ºC, desiccated. In lyophilized form, the chemical is stable for 24 months. Once in solution, store at -20ºC and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

    Fluorescent Properties

    • Excitation maximum = 458 nm
    • Emission maximum = 590 nm

    Product Description

    Molecular Weight 1183.3 g/mol
    Purity >98%
    Molecular Formula C57H82O26
    CAS 7059-24-7
    Solubility Soluble in DMSO at 20 mg/mL.

    Background

    Chromomycin A3 is an antibiotic that binds to the GC-rich sequence of DNA in the presence of divalent cations, inhibiting DNA replication and transcription (1). It is also used as a fluorescent DNA stain, and is particularly useful in staining human sperm chromatin in fertility and protamine deficiency studies (2). An analog of Mithramycin A, Chromomycin A3 displays many of the same DNA-binding and transcriptional regulation properties. For example, Chromomycin A3 suppresses a similar set of specificity protein 1 (SP1)-related anti-apoptotic proteins as Mithramycin A, and effectively inhibits cell proliferation more strongly than Mithramycin A. In a comparative treatment of cervical cancer cells, Chromomycin A3 displayed an IC50 that was 4-10 times higher than the same cells treated with Mithramycin A. In several clinical studies, Chromomycin A3 exhibited anti-cancer effects in individuals with breast cancer, Hodgkin's disease, lung adenocarcinoma, melanoma, and rhabdomyosarcoma; however, there were also inconsistent treatment results and some harmful side effects (3).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.